Merck & Co. Inc. (NYSE: MRK) and Endocyte Inc. (Nasdaq: ECYT) will jointly develop and commercialize Endocyte's late stage cancer drug candidate EC145. Shares of Merck rose 21 cents to $37.99 while Endocyte stock more than doubled by surging $3.88 to $7.68.